We Use NK Cells to Fight Disease

At Dragonfly we invent novel therapies that harness the body's
immune system, for vastly improved patient outcomes.

DRAGONFLY IN THE NEWS

Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors

3d-illustration-of-a-cancer-cell-and-lym

Dragonfly Therapeutics Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

Cell..jpg

Our Partners

BMS.png
1280px-Merck_Logo.svg.png
abbvie logo 4.png
UCBerk.png
logo-mit-png-mit-logo-793.png
Cornell-University.png
u-chi.gif
Signature_Stacked_Purple_Hex.png
DKFZ_Logo-3zu-Research_en_Black-Blue_sRG
MDA Logo.png
UCSFHealthLogo17_radiology_white.png
stanford-white.png
CancerDeath-Chart2.png

THE LATEST AT DRAGONFLY THERAPEUTICS

THE CHALLENGE

Cancer is the Leading Cause of Death Worldwide

INSPIRATION

Breakthrough Discoveries,  Renegade Scientists, and Patients Fighting Disease That We Find Inspiring

Sep082016_0084_preview.jpeg

OUR TECHNOLOGY

iStock-824641956 (1).jpg

Dragonfly's Proprietary TriNKETs Activate the Body's NK Cells and Mobilize T Cells + Other Cells of the Adaptive Immune System